Cargando…

New developments in transcatheter therapy of mitral valve disease

Mitral valve regurgitation (MR) belongs to one of the most common acquired valve diseases in western countries with increasing prevalence in older age. For patients with high perioperative risk and older age prohibitive for valve surgery, the development of transcatheter mitral valve therapies offer...

Descripción completa

Detalles Bibliográficos
Autores principales: Walther, Claudia, Fichtlscherer, Stephan, Holubec, Tomas, Vasa-Nicotera, Mariuca, Arsalan, Mani, Walther, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212154/
https://www.ncbi.nlm.nih.gov/pubmed/32395315
http://dx.doi.org/10.21037/jtd.2019.12.137
_version_ 1783531564615860224
author Walther, Claudia
Fichtlscherer, Stephan
Holubec, Tomas
Vasa-Nicotera, Mariuca
Arsalan, Mani
Walther, Thomas
author_facet Walther, Claudia
Fichtlscherer, Stephan
Holubec, Tomas
Vasa-Nicotera, Mariuca
Arsalan, Mani
Walther, Thomas
author_sort Walther, Claudia
collection PubMed
description Mitral valve regurgitation (MR) belongs to one of the most common acquired valve diseases in western countries with increasing prevalence in older age. For patients with high perioperative risk and older age prohibitive for valve surgery, the development of transcatheter mitral valve therapies offers new options. Assessment of the severity and etiology of MR and thorough imaging of the mitral valve anatomy and pathology are necessary prerequisites for appropriate decision making in the field of transcatheter mitral valve therapies. Different transcatheter repair and replacement techniques are on the market, most of them mimicking surgical techniques. With some techniques (e.g., the MitraClip device), there is good clinical experience (>80,000 devices implanted worldwide), and evidence (three randomized studies), whereas for newer procedures, safety and efficacy data are still very limited. Transcatheter mitral repair and replacement techniques have to be considered as complementary treatment options for high-risk patients indicated by the Heart Teams. The different techniques and devices will be introduced and discussed in the following paper.
format Online
Article
Text
id pubmed-7212154
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-72121542020-05-11 New developments in transcatheter therapy of mitral valve disease Walther, Claudia Fichtlscherer, Stephan Holubec, Tomas Vasa-Nicotera, Mariuca Arsalan, Mani Walther, Thomas J Thorac Dis Review Article on Interventional Cardiology Mitral valve regurgitation (MR) belongs to one of the most common acquired valve diseases in western countries with increasing prevalence in older age. For patients with high perioperative risk and older age prohibitive for valve surgery, the development of transcatheter mitral valve therapies offers new options. Assessment of the severity and etiology of MR and thorough imaging of the mitral valve anatomy and pathology are necessary prerequisites for appropriate decision making in the field of transcatheter mitral valve therapies. Different transcatheter repair and replacement techniques are on the market, most of them mimicking surgical techniques. With some techniques (e.g., the MitraClip device), there is good clinical experience (>80,000 devices implanted worldwide), and evidence (three randomized studies), whereas for newer procedures, safety and efficacy data are still very limited. Transcatheter mitral repair and replacement techniques have to be considered as complementary treatment options for high-risk patients indicated by the Heart Teams. The different techniques and devices will be introduced and discussed in the following paper. AME Publishing Company 2020-04 /pmc/articles/PMC7212154/ /pubmed/32395315 http://dx.doi.org/10.21037/jtd.2019.12.137 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article on Interventional Cardiology
Walther, Claudia
Fichtlscherer, Stephan
Holubec, Tomas
Vasa-Nicotera, Mariuca
Arsalan, Mani
Walther, Thomas
New developments in transcatheter therapy of mitral valve disease
title New developments in transcatheter therapy of mitral valve disease
title_full New developments in transcatheter therapy of mitral valve disease
title_fullStr New developments in transcatheter therapy of mitral valve disease
title_full_unstemmed New developments in transcatheter therapy of mitral valve disease
title_short New developments in transcatheter therapy of mitral valve disease
title_sort new developments in transcatheter therapy of mitral valve disease
topic Review Article on Interventional Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212154/
https://www.ncbi.nlm.nih.gov/pubmed/32395315
http://dx.doi.org/10.21037/jtd.2019.12.137
work_keys_str_mv AT waltherclaudia newdevelopmentsintranscathetertherapyofmitralvalvedisease
AT fichtlschererstephan newdevelopmentsintranscathetertherapyofmitralvalvedisease
AT holubectomas newdevelopmentsintranscathetertherapyofmitralvalvedisease
AT vasanicoteramariuca newdevelopmentsintranscathetertherapyofmitralvalvedisease
AT arsalanmani newdevelopmentsintranscathetertherapyofmitralvalvedisease
AT waltherthomas newdevelopmentsintranscathetertherapyofmitralvalvedisease